Omeros Corporation is a biopharmaceutical company that develops and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, and immune-related diseases. The company's product OMIDRIA is used during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain. The company's other products include Narsoplimab, OMS906, and OMS527. Omeros Corporation was founded in 1994 and is headquartered in Seattle, Washington.